

Efficacy of treatments targeting hypothalamic-pituitary-adrenal systems for major depressive disorder: a meta-analysis

Yudan Ding¹, Zirou Wei¹, Haohao Yan¹, and Wenbin Guo¹

¹Second Xiangya Hospital Department of Psychiatry



March 07, 2024


Abstract

Abnormal hypothalamic-pituitary-adrenal (HPA) axis has been implicated in major depressive disorder (MDD). The aims of this meta-analysis were to determine the effect and safety profile of HPA-targeting medications for MDD. World of Science and PubMed databases were comprehensively searched up to March 2021. All randomized controlled trials (RCTs) and open-label trials exploring antiglucocorticoid and related medications in patients with depression were included. In the meta-analysis, we identified 16 RCTs and seven open-label studies that included 2972 subjects. Our study suggested that patients with MDD may benefit from mifepristone and V1B receptor antagonist treatments that have tolerable side effects. HPA-based medications are promising for depression treatment. However, additional high-quality RCTs, including head-to-head trials, are needed.

Hosted file

manuscript5.docx available at <https://authorea.com/users/730937/articles/710302-efficacy-of-treatments-targeting-hypothalamic-pituitary-adrenal-systems-for-major-depressive-disorder-a-meta-analysis>





Hosted file

Table 1.docx available at <https://authorea.com/users/730937/articles/710302-efficacy-of-treatments-targeting-hypothalamic-pituitary-adrenal-systems-for-major-depressive-disorder-a-meta-analysis>

Hosted file

Table 2.docx available at <https://authorea.com/users/730937/articles/710302-efficacy-of-treatments-targeting-hypothalamic-pituitary-adrenal-systems-for-major-depressive-disorder-a-meta-analysis>